IN8bio, Inc. (INAB)

Market Cap	13.07M
Revenue (ttm)	n/a
Net Income (ttm)	-30.44M
Shares Out	81.26M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	467,534
Open	0.1591
Previous Close	0.1576
Day's Range	0.1577 - 0.1608
52-Week Range	0.1330 - 1.7400
Beta	0.24
Analysts	Strong Buy
Price Target	3.60 (+2,159.89%)
Earnings Date	May 8, 2025

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to tre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: INAB
• Website: https://in8bio.com

Analyst Forecast

According to 2 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $3.6, which is an increase of 2,159.89% from the latest price.

Price Target

$3.6

(2,159.89% upside)

Analyst Consensus: Strong Buy